News – Page 1168 – Endpoints News

Alzheimer’s player gets $47M, a new name and a pair of marquee board members

9 years ago

$33M in hand, Rigontec opens an office in Cambridge and sets sights on its first immuno-oncology trial

9 years ago

Protocols: CoLucid shares rocket up on positive migraine PhIII; Sage bags a 'breakthrough' on post-partum depression

9 years ago

Allergan bags an early-stage gene therapy in $60M RetroSense buyout

9 years ago

Allergan CEO Brent Saunders takes a pricing pledge: Predatory practices must end

9 years ago

After landing a $354M payout, Medivation CEO David Hung doesn’t overlook his 2016 bonus

9 years ago

Karyopharm sets a course for the FDA with positive PhIIb multiple myeloma data

9 years ago

AstraZeneca offers some mixed PhIII results for severe asthma, while Roche rival flounders

9 years ago

Novartis’ CAR-T chief Azam is leaving, but pharma giant denies any ‘retreat’ is underway

9 years ago

Protocols: Hillary Clinton takes aim at drug profiteers; Arena spins out a GPCR biotech incubator

9 years ago

Thumbs Up/Thumbs Down: Novartis's retreat leaves plenty of casualties; Biogen orchestrates a shameful media show, and ...

9 years ago

Stroke risk forces Merck to scrap its long-neglected PhIII osteoporosis drug odanacatib

9 years ago

Scoop: Novartis’ retreat on CAR-T includes axing most of its senior execs on the team

9 years ago

Momenta’s failed pancreatic cancer drug is given a midnight funeral

9 years ago

Protocols: Novo chief Sørensen is handing over the reins early; Cytokinetics moves Amgen-partnered heart drug into ...

9 years ago

Roger Tsien, 1952-2016: “I’ve always been attracted to colors”

9 years ago

Who’s been dipping their fingers into the till at Parexel?

9 years ago

Roche racks up another checkpoint win as Tecentriq scores in latest PhIII lung cancer study

9 years ago

Sunovion bags PhIII Parkinson’s drug in $624M Cynapsus buyout

9 years ago

Biogen hypes a fresh set of early, upbeat results for Alzheimer’s drug

9 years ago

Scoop: Novartis disbands its pioneering cell and gene therapy unit

9 years ago

$354M exit package in hand, Medivation CEO David Hung completes a master class in biotech auctions

9 years ago

Protocols: With Ninlaro sales suffering, Takeda launches huge multiple myeloma study; Medivir splitting, spinning R&D ...

9 years ago

Abandoned in PhIII, Onconova sacrifices more staffers to its survival strategy

9 years ago

First page Previous page 1165 1166 116711681169 1170 1171 Next page Last page